Literature DB >> 27057458

Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma.

Sherille D Bradley1, Brenda Melendez1, Amjad Talukder1, Gregory Lizée1.   

Abstract

Several studies have demonstrated that oncogenic BRAF(V600E) promotes T-cell suppression in melanoma by upregulating the transcription of a multitude of immunomodulatory chemokine and cytokine genes. BRAF(V600E) has now been shown to act even more directly to evade cytotoxic T-cell recognition, by driving rapid internalization of human leukocyte antigen (HLA) class I from the tumor-cell surface and its intracellular sequestration.

Entities:  

Keywords:  BRAF V600E; Cancer; Cytotoxic T cell; HLA; MHC class I; immune suppression; immunotherapy; interleukin-1; melanoma; oncogene; oncogene targeted therapies

Year:  2015        PMID： 27057458      PMCID： PMC4801458          DOI： 10.1080/2162402X.2015.1078966

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Tails of wonder: endocytic-sorting motifs key for exogenous antigen presentation.

Authors:  Gregory Lizée; Genc Basha; Wilfred A Jefferies
Journal:  Trends Immunol       Date:  2005-03       Impact factor: 16.687

2.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

3.  BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.

Authors:  Sherille D Bradley; Zeming Chen; Brenda Melendez; Amjad Talukder; Jahan S Khalili; Tania Rodriguez-Cruz; Shujuan Liu; Mayra Whittington; Wanleng Deng; Fenge Li; Chantale Bernatchez; Laszlo G Radvanyi; Michael A Davies; Patrick Hwu; Gregory Lizée
Journal:  Cancer Immunol Res       Date:  2015-03-20       Impact factor: 11.151

4.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

Review 5.  Harnessing the power of the immune system to target cancer.

Authors:  Gregory Lizée; Willem W Overwijk; Laszlo Radvanyi; Jianjun Gao; Padmanee Sharma; Patrick Hwu
Journal:  Annu Rev Med       Date:  2012-10-22       Impact factor: 13.739

6.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

7.  BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Authors:  Chengwen Liu; Weiyi Peng; Chunyu Xu; Yanyan Lou; Minying Zhang; Jennifer A Wargo; Jie Qing Chen; Haiyan S Li; Stephanie S Watowich; Yan Yang; Dennie Tompers Frederick; Zachary A Cooper; Rina M Mbofung; Mayra Whittington; Keith T Flaherty; Scott E Woodman; Michael A Davies; Laszlo G Radvanyi; Willem W Overwijk; Gregory Lizée; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

8.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

9.  Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.

Authors:  Jahan S Khalili; Shujuan Liu; Tania G Rodríguez-Cruz; Mayra Whittington; Seth Wardell; Chengwen Liu; Minying Zhang; Zachary A Cooper; Dennie T Frederick; Yufeng Li; Min Zhang; Richard W Joseph; Chantale Bernatchez; Suhendan Ekmekcioglu; Elizabeth Grimm; Laszlo G Radvanyi; Richard E Davis; Michael A Davies; Jennifer A Wargo; Patrick Hwu; Gregory Lizée
Journal:  Clin Cancer Res       Date:  2012-07-31       Impact factor: 12.531

10.  The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.

Authors:  Hidetoshi Sumimoto; Fumie Imabayashi; Tomoko Iwata; Yutaka Kawakami
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307
  10 in total
  5 in total

1.  SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Authors:  Jungsun Park; Amjad H Talukder; Seon A Lim; Kwanghee Kim; Ke Pan; Brenda Melendez; Sherille D Bradley; Kyle R Jackson; Jahan S Khalili; Junmei Wang; Caitlin Creasy; Bih-Fang Pan; Scott E Woodman; Chantale Bernatchez; David Hawke; Patrick Hwu; Kyung-Mi Lee; Jason Roszik; Gregory Lizée; Cassian Yee
Journal:  Cancer Immunol Res       Date:  2017-06-19       Impact factor: 11.151

Review 2.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

Review 3.  Cancer Immunotherapy: Whence and Whither.

Authors:  Peter J Stambrook; John Maher; Farzin Farzaneh
Journal:  Mol Cancer Res       Date:  2017-03-29       Impact factor: 5.852

4.  Disrupting ATF4 Expression Mechanisms Provides an Effective Strategy for BRAF-Targeted Melanoma Therapy.

Authors:  Ikuko Nagasawa; Masaru Koido; Yuri Tani; Satomi Tsukahara; Kazuhiro Kunimasa; Akihiro Tomida
Journal:  iScience       Date:  2020-03-31

5.  Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer.

Authors:  Theodoros Michelakos; Filippos Kontos; Tomohiro Kurokawa; Lei Cai; Ananthan Sadagopan; Danielle Krijgsman; Wilko Weichert; Lindy G Durrant; Peter J K Kuppen; Cristina R Ferrone; Soldano Ferrone
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.